Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047749 · ClinicalTrials.gov registry record · Phase 3
Prialt (Ziconotide) In Severe Chronic Pain
A Phase 3 study, sponsored by Elan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00047749 is a Phase 3 study that has completed, run by Elan Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT00047749, a Phase 3 study, has completed, sponsored by Elan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects of intrathecal ziconotide (an experimental pain medication) when the dose is slowly increased over a 3-week period in patients with severe chronic pain. During the weaning phase, the study will also gather information about switching from other intrathecal or IT medication (slowly pumped directly into the space around the spine) to other systemic pain medication (by mouth or through the skin using a patch). After being weaned off current IT medication, patients will be placed on IT ziconotide or placebo (non-active substance) as well as being allowed a stable dose of systemic pain medications. Patients who complete this study may be eligible for long-term ziconotide therapy via extension protocol ELN92045-352.
Interventions
- DRUG Prialt (ziconotide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047749
The ClinicalTrials.gov registry entry for NCT00047749 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elan Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prialt (ziconotide) is the first listed.
NCT00047749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047749 about?
NCT00047749 is a clinical study titled "Prialt (Ziconotide) In Severe Chronic Pain". The purpose of this study is to understand the effects of intrathecal ziconotide (an experimental pain medication) when the dose is slowly increased over a 3-week period in patients with severe chronic pain. During the weaning phase, the study will also gather information about switching from other ...
What is the current status of trial NCT00047749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2002-08. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00047749?
The interventions under investigation include: Prialt (ziconotide) (DRUG).
Who is sponsoring clinical trial NCT00047749?
This trial is sponsored by Elan Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.